Pluristem Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics

PSTI 8.720

+0.2%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: xcentral1	5/5/2010 9:01:08 AM
	of 295

Pluristem Therapeutics' Dr. William Prather Interviewed on CorporateProfile.com NEW YORK, NY, May 05, 2010 (MARKETWIRE via COMTEX) -- Corporate Profile, LLC announced today that Pluristem Therapeutics, Inc. (NASDAQ: PSTI) VP of Corporate Development, Dr. William Prather, was interviewed on CorporateProfile.com. Pluristem has recently announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The interim data demonstrated that PLX-PAD is safe, well tolerated and effective. The video can be viewed at: corporateprofile.com. About Pluristem Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. For more information visit the company website at pluristem.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next